上海交通大学内科学专业导师介绍：吴凌云

作者	论文标题	期刊名	出版年	卷期页码
张耀,宋陆茜,吴凌云 （通讯作者）,常春康,李晓	p15INK4B甲基化与骨髓增生异常综合征患者预后及地西他滨疗效的关系	中华血液学杂志	2013	34(3) :237-241
Zhang X, Chang C, Zhao Y, Wu L, Zhang Z, Li X.	The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients.	Hematology	2012	17(5):255-60.
Wu L, Li X, Xu F, Chang C, He Q, Zhang Z, Zhang Y.	Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34(+) cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.	Ann Hematol.	2012	91 (10):1547-1554
Xu F, Wu L, He Q, Zhang Z, Chang C, Li X.	Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes.	Intern Med J	2012	42(4):401-11.
Xu F, Yang R, Wu L, He Q, Zhang Z, Zhang Q, Yang Y, Guo J, Chang C, Li X.	Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.	Cancer Lett.	2012	317(1):33-40
Xiao L, Qi Z, Qiusheng C, Li X, Luxi S, Lingyun W.	The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.	Am J Hematol.	2012	87(1):26-31.
Yang Y, Zhang Q, Xu F, Wu L, He Q, Li X.	Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome.	J Cancer Res Clin Oncol.	2012	138(5):729-37
Zhang Y, Wu L （共同第一作者）, et al.	Low RPS14 gene expression is accompanied by p53-independent apoptosis in MDS patients with 5q- aberrations.	HealthMED	2012	6(7):2456-2463
Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, Zhang Z, He Q, Chang C.	Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.	Ann Hematol.	2011	90(6):643-53
Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q.	Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.	J Cancer Res Clin Oncol	2011	137(10):1563-9.
Zheng Z, Feng X, Xiao L, Qianqiao Z, Qi H, Lingyun W.	Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes.	Eur J Haematol.	2011	86(1):47-56.
Li X, Xu F, He Q, Wu L, Zhang Z, Chang C.	Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA).	Intern Med	2010	49(14):1349-55.
Xu F, Li X, Wu L, He Q, Zhang Z, Chang C.	Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.	Br J Haematol	2010	149(4):587-97
Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q.	Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.	Leuk Lymphoma	2009	50(9):1461-7